327 related articles for article (PubMed ID: 37842234)
1. Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
Astore S; Baciarello G; Cerbone L; Calabrò F
Cancer Drug Resist; 2023; 6(3):517-546. PubMed ID: 37842234
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
Sekino Y; Teishima J; Liang G; Hinata N
Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
[TBL] [Abstract][Full Text] [Related]
3. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
4. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
5. Emerging resistance
Roy AM; George S
Cancer Drug Resist; 2023; 6(3):642-655. PubMed ID: 37842239
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.
Lai Y; Zhao Z; Zeng T; Liang X; Chen D; Duan X; Zeng G; Wu W
Cancer Cell Int; 2018; 18():31. PubMed ID: 29527128
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.
Sweeney PL; Suri Y; Basu A; Koshkin VS; Desai A
Cancer Drug Resist; 2023; 6(4):858-873. PubMed ID: 38239394
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
9. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Tannir N; Hammers H; Amin A
Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
[TBL] [Abstract][Full Text] [Related]
10. Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.
Kamli H; Li L; Gobe GC
Ochsner J; 2019; 19(2):138-151. PubMed ID: 31258426
[No Abstract] [Full Text] [Related]
11. IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Rizzo M; Varnier L; Pezzicoli G; Pirovano M; Cosmai L; Porta C
Front Oncol; 2022; 12():990568. PubMed ID: 36059687
[TBL] [Abstract][Full Text] [Related]
12. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
13. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
[TBL] [Abstract][Full Text] [Related]
15. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.
Mollica V; Di Nunno V; Gatto L; Santoni M; Scarpelli M; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Montironi R; Massari F
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31207938
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
[TBL] [Abstract][Full Text] [Related]
17. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment in renal cell carcinoma: clinical experience and decision making.
Guadalupi V; Cartenì G; Iacovelli R; Porta C; Pappagallo G; Ricotta R; Procopio G
Ther Adv Urol; 2021; 13():17562872211022870. PubMed ID: 34211586
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
20. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]